Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Molly C Carr

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Journal of Lipid Research|February 28, 2002
Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurementSusan J Murdoch, Gertrud Wolfbauer, Hal Kennedy, et al.
Diabetologia|September 12, 2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaPeter N Weissman, Molly C Carr, June Ye, et al.
Diabetes Care|July 23, 2014
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III studyLawrence A Leiter, Molly C Carr, Murray Stewart, et al.
Diabetes Research and Clinical Practice|March 12, 2017
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trialsBo Ahrén, Molly C Carr, Karen Murphy, et al.
Current Medical Research and Opinion|November 18, 2016
Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugsInaha Okuda, Timothy H Wilson, Lin Yue, et al.
Journal of Diabetes Investigation|September 19, 2017
Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled studyAntonio Nino, Inaha Okuda, Timothy H Wilson, et al.
Diabetes Care|July 23, 2020
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized TrialJulio Rosenstock, Antonio Nino, Joseph Soffer, et al.
Lancet (London, England)|September 13, 2024
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trialRichard M Bergenstal, Ruth S Weinstock, Chantal Mathieu, et al.
The New England Journal of Medicine|June 23, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin TherapyJulio Rosenstock, Timothy Bailey, Lisa Connery, et al.
Diabetes, Obesity & Metabolism|April 29, 2024
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programmeRichard M Bergenstal, Athena Philis-Tsimikas, Carol Wysham, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of Lipid Research|February 28, 2002
Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurementSusan J Murdoch, Gertrud Wolfbauer, Hal Kennedy, et al.
Diabetologia|September 12, 2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaPeter N Weissman, Molly C Carr, June Ye, et al.
Diabetes Care|July 23, 2014
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III studyLawrence A Leiter, Molly C Carr, Murray Stewart, et al.
Diabetes Research and Clinical Practice|March 12, 2017
Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trialsBo Ahrén, Molly C Carr, Karen Murphy, et al.
Current Medical Research and Opinion|November 18, 2016
Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugsInaha Okuda, Timothy H Wilson, Lin Yue, et al.
Journal of Diabetes Investigation|September 19, 2017
Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled studyAntonio Nino, Inaha Okuda, Timothy H Wilson, et al.
Diabetes Care|July 23, 2020
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized TrialJulio Rosenstock, Antonio Nino, Joseph Soffer, et al.
Lancet (London, England)|September 13, 2024
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trialRichard M Bergenstal, Ruth S Weinstock, Chantal Mathieu, et al.
The New England Journal of Medicine|June 23, 2025
Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin TherapyJulio Rosenstock, Timothy Bailey, Lisa Connery, et al.
Diabetes, Obesity & Metabolism|April 29, 2024
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programmeRichard M Bergenstal, Athena Philis-Tsimikas, Carol Wysham, et al.
Pageof 3